

Author index of volume 57

- Aizawa, Y., see Suzuki, K. 57, 179
 Alberti, G., see Azzopardi, J. 57, 87
 Asami, K., see Komiyama, N. 57, 163
 Astorga, R., see Relimpio, F. 57, 199
 Azzopardi, J., A. Gatt, A. Zammit, G. Alberti, Lack of evidence of cerebral oedema in adults treated for diabetic ketoacidosis with fluids of different tonicity 57, 87
 Barzi, F., see Watanabe, M. 57, 191
 Benedí, A., see Calle-Pascual, A.L. 57, 111
 Bouter, L.M., see de Vegt, F. 57, 53
 Cabezas-Cerrato, J., see Calle-Pascual, A.L. 57, 111
 Calle, J.R., see Calle-Pascual, A.L. 57, 111
 Calle-Pascual, A.L., A. Durán, A. Benedí, M.I. Calvo, A. Charro, J.A. Díaz, J.R. Calle, E. Gil, J.P. Marañes, J. Cabezas-Cerrato, A preventative foot care programme for people with diabetes with different stages of neuropathy 57, 111
 Calvo, M.I., see Calle-Pascual, A.L. 57, 111
 Cameron, A.J., see Dunstan, D.W. 57, 119
 Canbay, E., see Dökmataş, H.S. 57, 139
 Çelik, P., see Özmen, B. 57, 209
 Charro, A., see Calle-Pascual, A.L. 57, 111
 Chow, C.C., see Tong, P.C. 57, 93
 Cockram, C.S., see Tong, P.C. 57, 93
 Çok, G., see Özmen, B. 57, 209
 Cyganek, K., see Malecki, M.T. 57, 99
 Daniel, M., K.G. Rowley, R. McDermott, K. O'Dea, Diabetes and impaired glucose tolerance in Aboriginal Australians: prevalence and risk 57, 23
 De Alvaro, F., see Esmatjes, E. 57, 35
 de Alwis, N.M.W., see Malavige, G.N. 57, 143
 de Courten, M., see Dunstan, D.W. 57, 119
 Deeb, S.S., see Nemoto, M. 57, 131
 Dekker, J.M., see de Vegt, F. 57, 53
 de Vegt, F., J.M. Dekker, W.-J.A. Groeneveld, G. Nijpels, C.D.A. Stehouwer, L.M. Bouter, R.J. Heine, Moderate alcohol consumption is associated with lower risk for incident diabetes and mortality: the Hoorn Study 57, 53
 Diaz, J.A., see Calle-Pascual, A.L. 57, 111
 Dökmataş, H.S., E. Canbay, S. Yilmaz, N. Elaldi, A. Topalkara, İ. Öztoprak, E. Yildiz, Diabetic ketoacidosis and rhino-orbital mucormycosis 57, 139
 Dunstan, D.W., P.Z. Zimmet, T.A. Welborn, A.J. Cameron, J. Shaw, M. de Courten, D. Jolley, D.J. McCarty, The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)—methods and response rates 57, 119
 Durán, A., see Calle-Pascual, A.L. 57, 111
 Elaldi, N., see Dökmataş, H.S. 57, 139
 Esmatjes, E., F. De Alvaro, Incidence of diabetic nephropathy in Type 1 diabetic patients in Spain: 'Estudio Diamante' 57, 35
 Fernando, D.J.S., see Malavige, G.N. 57, 143
 Frey, J., see Malecki, M.T. 57, 99
 Fujii, S., see Yamakita, T. 57, 17
 Fujimoto, W.Y., see Nemoto, M. 57, 131
 Gatt, A., see Azzopardi, J. 57, 87
 Gil, E., see Calle-Pascual, A.L. 57, 111
 Gorogawa, S.-i., Y. Kajimoto, Y. Umayahara, H. Kaneto, H. Watada, A. Kuroda, D. Kawamori, T. Yasuda, M. Matsuhisa, Y. Yamasaki, M. Hori, Probuco preserves pancreatic β -cell function through reduction of oxidative stress in type 2 diabetes 57, 1
 Groeneveld, W.-J.A., see de Vegt, F. 57, 53
 Hayakawa, T., see Kahara, T. 57, 105
 Heine, R.J., see de Vegt, F. 57, 53
 Hirai, H., Y. Kaino, T. Ito, K. Takemoto, A. Ishimaru, S. Watanabe, K. Kida, Early detection of infantile pre-type 1 diabetes case with transient hyperglycemia 57, 83
 Hirashima, T., see Luan, Y. 57, 75
 Hori, M., see Gorogawa, S.-i. 57, 1
 Hosoi, M., see Yamakita, T. 57, 17

- Ikarashi, T., see Suzuki, K. 57, 179
- Imazu, M., K. Sumii, H. Yamamoto, M. Toyofuku, F. Tadehara, M. Okubo, M. Yamakido, N. Kohno, A.T. Onaka, Influence of type 2 diabetes mellitus on cardiovascular disease mortality: findings from the Hawaii-Los Angeles-Hiroshima study 57, 61
- Ishii, T., see Yamakita, T. 57, 17
- Ishimaru, A., see Hirai, H. 57, 83
- Ito, T., see Hirai, H. 57, 83
- Jolley, D., see Dunstan, D.W. 57, 119
- Jorgensen, L.N., see Tong, P.C. 57, 93
- Joseph, S., see Ramachandran, A. 57, 185
- Kahara, T., T. Takamura, T. Hayakawa, Y. Nagai, H. Yamaguchi, T. Katsuki, K.-i. Katsuki, M. Katsuki, K.-i. Kobayashi, Prediction of exercise-mediated changes in metabolic markers by gene polymorphism 57, 105
- Kaino, Y., see Hirai, H. 57, 83
- Kajimoto, Y., see Gorogawa, S.-i. 57, 1
- Kaneko, S., see Suzuki, K. 57, 179
- Kaneko, T., see Komiyama, N. 57, 163
- Kaneto, H., see Gorogawa, S.-i. 57, 1
- Katsuki, K.-i., see Kahara, T. 57, 105
- Katsuki, M., see Kahara, T. 57, 105
- Katsuki, T., see Kahara, T. 57, 105
- Kawamori, D., see Gorogawa, S.-i. 57, 1
- Kawano, K., see Luan, Y. 57, 75
- Kida, K., see Hirai, H. 57, 83
- Klupa, T., see Malecki, M.T. 57, 99
- Kobayashi, K.-i., see Kahara, T. 57, 105
- Kohno, N., see Imazu, M. 57, 61
- Komiyama, N., T. Kaneko, A. Sato, W. Sato, K. Asami, T. Onaya, M. Tawata, The effect of high carbohydrate diet on glucose tolerance in patients with type 2 diabetes mellitus 57, 163
- Kuroda, A., see Gorogawa, S.-i. 57, 1
- Lee, Y.S., see Todd, A.L. 57, 171
- Loke, K.Y., see Todd, A.L. 57, 171
- Losada, F., see Relimpio, F. 57, 199
- Luan, Y., T. Hirashima, Z.-W. Man, M.-W. Wang, K. Kawano, T. Sumida, Pathogenesis of obesity by food restriction in OLETF rats-increased intestinal monoacylglycerol acyltransferase activities may be a crucial factor 57, 75
- Makino, H., see Yamashita, T. 57, 149
- Malavige, G.N., N.M.W. de Alwis, S.H. Siribaddana, N. Weerasooriya, D.J.S. Fernando, Increasing diabetes and vascular risk factors in a sub-urban Sri Lankan population 57, 143
- Malecki, M.T., T. Klupa, K. Wanic, K. Cyganek, J. Frey, J. Sieradzki, Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population 57, 99
- Mangas, M.A., see Relimpio, F. 57, 199
- Man, Z.-W., see Luan, Y. 57, 75
- Marañes, J.P., see Calle-Pascual, A.L. 57, 111
- Martinova, Y., see Ogneva, V. 57, 11
- Matsuda, M., see Yamashita, T. 57, 149
- Matsuhisa, M., see Gorogawa, S.-i. 57, 1
- McCarty, D.J., see Dunstan, D.W. 57, 119
- McDermott, R., see Daniel, M. 57, 23
- Miyamoto, M., see Yamakita, T. 57, 17
- Miyoshi, Y., see Watanabe, M. 57, 191
- Molyneaux, L., see Sorensen, L. 57, 45
- Morales, F., see Relimpio, F. 57, 199
- Nagai, Y., see Kahara, T. 57, 105
- Nakagawa, O., see Suzuki, K. 57, 179
- Neal, B., see Watanabe, M. 57, 191
- Nemoto, M., T. Sasaki, S.S. Deeb, W.Y. Fujimoto, N. Tajima, Differential effect of PPAR γ 2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans 57, 131
- Ng, W.-Y., see Todd, A.L. 57, 171
- Nijpels, G., see de Vegt, F. 57, 53
- O'Dea, K., see Daniel, M. 57, 23
- Ogawa, D., see Yamashita, T. 57, 149
- Ogneva, V., Y. Martinova, The effect of in vitro fibroblast growth factors on cell proliferation in pancreas from normal and streptozotocin-treated rats 57, 11
- Okada, S., see Yamashita, T. 57, 149
- Okayama, A., see Watanabe, M. 57, 191
- Okubo, M., see Imazu, M. 57, 61
- Onaka, A.T., see Imazu, M. 57, 61
- Onaya, T., see Komiyama, N. 57, 163
- Onishi, S., see Yamakita, T. 57, 17
- Özmen, B., P. Çelik, A. Yorgancıoğlu, B. Özmen, D. Özmen, G. Çok, Pulmonary function parameters in patients with diabetes mellitus 57, 209
- Özmen, B., see Özmen, B. 57, 209
- Özmen, D., see Özmen, B. 57, 209
- Öztoprak, İ., see Dökmetaş, H.S. 57, 139
- Pumar, A., see Relimpio, F. 57, 199
- Ramachandran, A., C. Snehalatha, R. Vinitha, M. Thayyil, C.K. Sathish Kumar, L. Sheeba, S. Joseph, V. Vijay, Prevalence of overweight in urban Indian adolescent school children 57, 185
- Relimpio, F., F. Losada, A. Pumar, M.A. Mangas, F. Morales, R. Astorga, Relationships of apolipoprotein B₁₀₀ with the metabolic syndrome in Type 2 diabetes mellitus 57, 199
- Reza Choudhury, S., see Watanabe, M. 57, 191
- Rowley, K.G., see Daniel, M. 57, 23
- Sasaki, T., see Nemoto, M. 57, 131
- Sathish Kumar, C.K., see Ramachandran, A. 57, 185
- Sato, A., see Komiyama, N. 57, 163
- Sato, T., see Yamakita, T. 57, 17
- Sato, W., see Komiyama, N. 57, 163

- Shaw, J., see Dunstan, D.W. 57, 119
- Sheeba, L., see Ramachandran, A. 57, 185
- Shikata, K., see Yamashita, T. 57, 149
- Sieradzki, J., see Malecki, M.T. 57, 99
- Siribaddana, S.H., see Malavige, G.N. 57, 143
- Snehalatha, C., see Ramachandran, A. 57, 185
- Sorensen, L., L. Molyneaux, D.K. Yue, Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control 57, 45
- Souda, S., see Suzuki, K. 57, 179
- Stehouwer, C.D.A., see de Vegt, F. 57, 53
- Sugimoto, H., see Yamashita, T. 57, 149
- Sumida, T., see Luan, Y. 57, 75
- Sumii, K., see Imazu, M. 57, 61
- Suzuki, K., S. Souda, T. Ikarashi, S. Kaneko, O. Nakagawa, Y. Aizawa, Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy 57, 179
- Tadehara, F., see Imazu, M. 57, 61
- Tajima, N., see Nemoto, M. 57, 131
- Takamura, T., see Kahara, T. 57, 105
- Takemoto, K., see Hirai, H. 57, 83
- Tanaka, S., see Yamakita, T. 57, 17
- Tawata, M., see Komiyama, N. 57, 163
- Thai, A.C., see Todd, A.L. 57, 171
- Thayyil, M., see Ramachandran, A. 57, 185
- Todd, A.L., W.-Y. Ng, Y.S. Lee, K.Y. Loke, A.C. Thai, Evidence of autoantibodies to glutamic acid decarboxylase in oral fluid of type 1 diabetic patients 57, 171
- Tong, P.C., C.C. Chow, L.N. Jorgensen, C.S. Cockram, The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin 57, 93
- Topalkara, A., see Dökmetaş, H.S. 57, 139
- Toyofuku, M., see Imazu, M. 57, 61
- Ueshima, H., see Watanabe, M. 57, 191
- Umayahara, Y., see Gorogawa, S.-i. 57, 1
- Vijay, V., see Ramachandran, A. 57, 185
- Vinitha, R., see Ramachandran, A. 57, 185
- Wada, J., see Yamashita, T. 57, 149
- Wang, M.-W., see Luan, Y. 57, 75
- Wanic, K., see Malecki, M.T. 57, 99
- Watada, H., see Gorogawa, S.-i. 57, 1
- Watanabe, M., F. Barzi, B. Neal, H. Ueshima, Y. Miyoshi, A. Okayama, S. Reza Choudhury, Alcohol consumption and the risk of diabetes by body mass index levels in a cohort of 5,636 Japanese 57, 191
- Watanabe, S., see Hirai, H. 57, 83
- Weerasooriya, N., see Malavige, G.N. 57, 143
- Welborn, T.A., see Dunstan, D.W. 57, 119
- Yamagami, K., see Yamakita, T. 57, 17
- Yamaguchi, H., see Kahara, T. 57, 105
- Yamakido, M., see Imazu, M. 57, 61
- Yamakita, T., T. Ishii, K. Yamagami, T. Yamamoto, M. Miyamoto, M. Hosoi, K. Yoshioka, T. Sato, S. Onishi, S. Tanaka, S. Fujii, Glycemic response during exercise after administration of insulin lispro compared with that after administration of regular human insulin 57, 17
- Yamamoto, H., see Imazu, M. 57, 61
- Yamamoto, T., see Yamakita, T. 57, 17
- Yamasaki, Y., see Gorogawa, S.-i. 57, 1
- Yamashita, T., K. Shikata, M. Matsuda, S. Okada, D. Ogawa, H. Sugimoto, J. Wada, H. Makino, Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating eNOS expression in diabetic rats 57, 149
- Yasuda, T., see Gorogawa, S.-i. 57, 1
- Yildiz, E., see Dökmetaş, H.S. 57, 139
- Yilmaz, S., see Dökmetaş, H.S. 57, 139
- Yorgancıoğlu, A., see Özmen, B. 57, 209
- Yoshioka, K., see Yamakita, T. 57, 17
- Yue, D.K., see Sorensen, L. 57, 45
- Zammit, A., see Azzopardi, J. 57, 87
- Zimmet, P.Z., see Dunstan, D.W. 57, 119



Subject index of volume 57

Aboriginal; Diabetes mellitus, type 2; Impaired glucose tolerance (IGT); Prevalence; Risk; Overweight, Obesity 57, 23

Adolescence; Obesity; Birth weight; Urbanization; India; Socio-economic factors; Childhood obesity 57, 185

β 3-Adrenergic receptor; Polymorphism; Uncoupling protein-1; Exercise; Leptin 57, 105

Adults; Diabetic ketoacidosis; Cerebral oedema; Hypotonic fluids; CT scan 57, 87

Alcohol consumption; Diabetes; BMI; Cohort study 57, 191

Alcohol; Mortality; Cumulative incidence; Glucose; Diabetes 57, 53

Antioxidant; Probucol; Glucose toxicity; Glucotoxicity; Oxidative stress 57, 1

Apolipoprotein B₁₀₀; Type 2 diabetes mellitus; Metabolic syndrome; Insulin resistance; Obesity; Microalbuminuria; Hypertension; Uric acid 57, 199

AusDiab; Response rates; Diabetes survey; Australia; Diabetes prevalence 57, 119

Australia; AusDiab; Response rates; Diabetes survey; Diabetes prevalence 57, 119

Birth weight; Obesity; Adolescence; Urbanization; India; Socio-economic factors; Childhood obesity 57, 185

BMI; Diabetes; Alcohol consumption; Cohort study 57, 191

Cardiovascular disease; Type 2 diabetes mellitus; Coronary heart disease; Hyperglycemia 57, 61

Cerebral oedema; Diabetic ketoacidosis; Adults; Hypotonic fluids; CT scan 57, 87

Childhood obesity; Obesity; Adolescence; Birth weight; Urbanization; India; Socio-economic factors 57, 185

Cohort study; Diabetes; Alcohol consumption; BMI 57, 191

Combination therapy; Metformin; Insulin; Type 2 diabetes 57, 93

Complications; Pain; Neuropathy; Gender; Diabetic foot 57, 45

Coronary heart disease; Type 2 diabetes mellitus; Cardiovascular disease; Hyperglycemia 57, 61

CT scan; Diabetic ketoacidosis; Cerebral oedema; Adults; Hypotonic fluids 57, 87

Cumulative incidence; Alcohol; Mortality; Glucose; Diabetes 57, 53

Diabetes; Alcohol consumption; BMI; Cohort study 57, 191

Diabetes; Alcohol; Mortality; Cumulative incidence; Glucose 57, 53

Diabetes; Fibroblast growth factor; Pancreas 57, 11

Diabetes mellitus; Foot at risk; Neuropathy; Neuropathy disability score; Vibration perception threshold; Foot ulcers; Prevention; Teaching and treatment program 57, 111

Diabetes mellitus, type 2; Aboriginal; Impaired glucose tolerance (IGT); Prevalence; Risk; Overweight, Obesity 57, 23

Diabetes prevalence; AusDiab; Response rates; Diabetes survey; Australia 57, 119

Diabetes survey; AusDiab; Response rates; Australia; Diabetes prevalence 57, 119

- Diabetic foot;** Pain; Neuropathy; Complications; Gender 57, 45
- Diabetic ketoacidosis;** Cerebral oedema; Adults; Hypotonic fluids; CT scan 57, 87
- Diabetic ketoacidosis;** Mucormycosis 57, 139
- Diabetic nephropathy;** Hyperfiltration; Prostacyclin; Nitric oxide; ICAM-1; Macrophage 57, 149
- Diabetic nephropathy;** Valsartan; Type 2 diabetes 57, 179
- Environment interaction;** Insulin resistance; Western lifestyle 57, 131
- Exercise;** Glycemic response; Insulin lispro; Regular human insulin 57, 17
- Exercise;** Polymorphism; β 3-Adrenergic receptor; Uncoupling protein-1; Leptin 57, 105
- Fibroblast growth factor;** Pancreas; Diabetes 57, 11
- Foot at risk;** Neuropathy; Neuropathy disability score; Vibration perception threshold; Foot ulcers; Prevention; Teaching and treatment program; Diabetes mellitus 57, 111
- Foot ulcers;** Foot at risk; Neuropathy; Neuropathy disability score; Vibration perception threshold; Prevention; Teaching and treatment program; Diabetes mellitus 57, 111
- Gender;** Pain; Neuropathy; Complications; Diabetic foot 57, 45
- Gingival crevicular fluid;** Immunoglobulin G; Mouth mucosa; Radio-immunoprecipitation assay; Transudate 57, 171
- Glucose;** Alcohol; Mortality; Cumulative incidence; Diabetes 57, 53
- Glucose tolerance;** High carbohydrate diet; HOMA-R; Insulinogenic index; LDL-cholesterol; HDL-cholesterol; Triglyceride 57, 163
- Glucose toxicity;** Probucol; Glucotoxicity; Oxidative stress; Antioxidant 57, 1
- Glucotoxicity;** Probucol; Glucose toxicity; Oxidative stress; Antioxidant 57, 1
- Glycemic response;** Exercise; Insulin lispro; Regular human insulin 57, 17
- HDL-cholesterol;** High carbohydrate diet; Glucose tolerance; HOMA-R; Insulinogenic index; LDL-cholesterol; Triglyceride 57, 163
- High carbohydrate diet;** Glucose tolerance; HOMA-R; Insulinogenic index; LDL-cholesterol; HDL-cholesterol; Triglyceride 57, 163
- HOMA-R;** High carbohydrate diet; Glucose tolerance; Insulinogenic index; LDL-cholesterol; HDL-cholesterol; Triglyceride 57, 163
- Hyperfiltration;** Diabetic nephropathy; Prostacyclin; Nitric oxide; ICAM-1; Macrophage 57, 149
- Hyperglycemia;** Type 2 diabetes mellitus; Cardiovascular disease; Coronary heart disease 57, 61
- Hypertension;** Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Metabolic syndrome; Insulin resistance; Obesity; Microalbuminuria; Uric acid 57, 199
- Hypotonic fluids;** Diabetic ketoacidosis; Cerebral oedema; Adults; CT scan 57, 87
- IA-2;** Transient hyperglycemia; Intravenous glucose tolerance test; Type 1 diabetes; Prediction 57, 83
- ICAM-1;** Diabetic nephropathy; Hyperfiltration; Prostacyclin; Nitric oxide; Macrophage 57, 149
- Immunoglobulin G;** Gingival crevicular fluid; Mouth mucosa; Radio-immunoprecipitation assay; Transudate 57, 171
- Impaired glucose tolerance (IGT);** Aboriginal; Diabetes mellitus, type 2; Prevalence; Risk; Overweight, Obesity 57, 23
- India;** Obesity; Adolescence; Birth weight; Urbanization; Socio-economic factors; Childhood obesity 57, 185
- Insulin lispro;** Exercise; Glycemic response; Regular human insulin 57, 17
- Insulin;** Metformin; Combination therapy; Type 2 diabetes 57, 93
- Insulinogenic index;** High carbohydrate diet; Glucose tolerance; HOMA-R; LDL-cholesterol; HDL-cholesterol; Triglyceride 57, 163
- Insulin resistance;** Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Metabolic syndrome; Obesity; Microalbuminuria; Hypertension; Uric acid 57, 199
- Insulin resistance;** Western lifestyle; Environment interaction 57, 131
- Intravenous glucose tolerance test;** Transient hyperglycemia; IA-2; Type 1 diabetes; Prediction 57, 83
- LDL-cholesterol;** High carbohydrate diet; Glucose tolerance;

- HOMA-R**; Insulinogenic index; HDL-cholesterol; Triglyceride 57, 163
- Leptin**; Polymorphism; β 3-Adrenergic receptor; Uncoupling protein-1; Exercise 57, 105
- Macrophage**; Diabetic nephropathy; Hyperfiltration; Prostacyclin; Nitric oxide; ICAM-1 57, 149
- Metabolic syndrome**; Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Insulin resistance; Obesity; Microalbuminuria; Hypertension; Uric acid 57, 199
- Metformin**; Combination therapy; Insulin; Type 2 diabetes 57, 93
- MGAT activity**; NIDDM; OLETF rat; Obesity 57, 75
- Microalbuminuria**; Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Metabolic syndrome; Insulin resistance; Obesity; Hypertension; Uric acid 57, 199
- Microalbuminuria**; Type 1 diabetes; Risk factors 57, 35
- Mortality**; Alcohol; Cumulative incidence; Glucose; Diabetes 57, 53
- Mouth mucosa**; Gingival crevicular fluid; Immunoglobulin G; Radio-immunoprecipitation assay; Transudate 57, 171
- Mucormycosis**; Diabetic ketoacidosis 57, 139
- Neuropathy disability score**; Foot at risk; Neuropathy; Vibration perception threshold; Foot ulcers; Prevention; Teaching and treatment program; Diabetes mellitus 57, 111
- Neuropathy**; Foot at risk; Neuropathy disability score; Vibration perception threshold; Foot ulcers; Prevention; Teaching and treatment program; Diabetes mellitus 57, 111
- Neuropathy**; Pain; Complications; Gender; Diabetic foot 57, 45
- NIDDM**; MGAT activity; OLETF rat; Obesity 57, 75
- Nitric oxide**; Diabetic nephropathy; Hyperfiltration; Prostacyclin; ICAM-1; Macrophage 57, 149
- Obesity**; Adolescence; Birth weight; Urbanization; India; Socio-economic factors; Childhood obesity 57, 185
- Obesity**; NIDDM; MGAT activity; OLETF rat 57, 75
- Obesity**; Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Metabolic syndrome; Insulin resistance; Microalbuminuria; Hypertension; Uric acid 57, 199
- OLETF rat**; NIDDM; MGAT activity; Obesity 57, 75
- Overweight, Obesity**; Aboriginal; Diabetes mellitus, type 2; Impaired glucose tolerance (IGT); Prevalence; Risk 57, 23
- Oxidative stress**; Probucol; Glucose toxicity; Glucotoxicity; Antioxidant 57, 1
- Pain**; Neuropathy; Complications; Gender; Diabetic foot 57, 45
- Pancreas**; Fibroblast growth factor; Diabetes 57, 11
- Polymorphism**; β 3-Adrenergic receptor; Uncoupling protein-1; Exercise; Leptin 57, 105
- Prediction**; Transient hyperglycemia; Intravenous glucose tolerance test; IA-2; Type 1 diabetes 57, 83
- Prevalence**; Aboriginal; Diabetes mellitus, type 2; Impaired glucose tolerance (IGT); Risk; Overweight, Obesity 57, 23
- Prevention**; Foot at risk; Neuropathy; Neuropathy disability score; Vibration perception threshold; Foot ulcers; Teaching and treatment program; Diabetes mellitus 57, 111
- Probucol**; Glucose toxicity; Glucotoxicity; Oxidative stress; Antioxidant 57, 1
- Prostacyclin**; Diabetic nephropathy; Hyperfiltration; Nitric oxide; ICAM-1; Macrophage 57, 149
- Radio-immunoprecipitation assay**; Gingival crevicular fluid; Immunoglobulin G; Mouth mucosa; Transudate 57, 171
- Regular human insulin**; Exercise; Glycemic response; Insulin lispro 57, 17
- Response rates**; AusDiab; Diabetes survey; Australia; Diabetes prevalence 57, 119
- Risk**; Aboriginal; Diabetes mellitus, type 2; Impaired glucose tolerance (IGT); Prevalence; Overweight, Obesity 57, 23
- Risk factors**; Type 1 diabetes; Microalbuminuria 57, 35
- Socio-economic factors**; Obesity; Adolescence; Birth weight; Urbanization; India; Childhood obesity 57, 185
- Teaching and treatment program**; Foot at risk; Neuropathy; Neuropathy disability score; Vibration perception threshold; Foot ulcers; Prevention; Diabetes mellitus 57, 111
- Transient hyperglycemia**; Intravenous glucose tolerance test; IA-2; Type 1 diabetes; Prediction 57, 83

Transudate; Gingival crevicular fluid; Immunoglobulin G; Mouth mucosa; Radio-immunoprecipitation assay 57, 171

Triglyceride; High carbohydrate diet; Glucose tolerance; HOMA-R; Insulinogenic index; LDL-cholesterol; HDL-cholesterol 57, 163

Type 2 diabetes; Diabetic nephropathy; Valsartan 57, 179

Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Metabolic syndrome; Insulin resistance; Obesity; Microalbuminuria; Hypertension; Uric acid 57, 199

Type 2 diabetes mellitus; Cardiovascular disease; Coronary heart disease; Hyperglycemia 57, 61

Type 2 diabetes mellitus; Vitamin D binding protein gene 57, 99

Type 2 diabetes; Metformin; Combination therapy; Insulin 57, 93

Type 1 diabetes; Microalbuminuria; Risk factors 57, 35

Type 1 diabetes; Transient hyperglycemia; Intravenous glucose tolerance test; IA-2; Prediction 57, 83

Uncoupling protein-1; Polymorphism; β 3-Adrenergic receptor; Exercise; Leptin 57, 105

Urbanization; Obesity; Adolescence; Birth weight; India; Socio-economic factors; Childhood obesity 57, 185

Uric acid; Type 2 diabetes mellitus; Apolipoprotein B₁₀₀; Metabolic syndrome; Insulin resistance; Obesity; Microalbuminuria; Hypertension 57, 199

Valsartan; Diabetic nephropathy; Type 2 diabetes 57, 179

Vibration perception threshold; Foot at risk; Neuropathy; Neuropathy disability score; Foot ulcers; Prevention; Teaching and treatment program; Diabetes mellitus 57, 111

Vitamin D binding protein gene; Type 2 diabetes mellitus 57, 99

Western lifestyle; Insulin resistance; Environment interaction 57, 131

